John Wilson
Director/Board Member en MARKER THERAPEUTICS, INC. .
Fortuna: 7 M $ al 31/03/2024
Perfil
Mr. John R.
Wilson is a Chief Executive Officer at Wilson Wolf Manufacturing Corp.
and an Independent Director at Marker Therapeutics, Inc. He is on the Board of Directors at Marker Therapeutics, Inc. Mr. Wilson was previously employed as an Independent Non-Executive Director by AlloVir, Inc., a Principal by Cellex Biosciences, Inc., and a Chief Executive Officer by Marker Cell Therapy, Inc. He received his undergraduate degree from Hamline University and an undergraduate degree from the University of Minnesota.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ALLOVIR INC
4.70% | 31/12/2023 | 5 355 877 ( 4.70% ) | 4 M $ | 31/03/2024 |
06/06/2023 | 781 200 ( 8.77% ) | 3 M $ | 31/03/2024 |
Cargos activos de John Wilson
Empresas | Cargo | Inicio |
---|---|---|
MARKER THERAPEUTICS, INC. | Director/Board Member | 17/10/2018 |
Wilson Wolf Manufacturing Corp.
Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Chief Executive Officer | 01/01/1998 |
Antiguos cargos conocidos de John Wilson.
Empresas | Cargo | Fin |
---|---|---|
ALLOVIR, INC. | Founder | 17/05/2022 |
Cellex Biosciences, Inc. | Corporate Officer/Principal | - |
Marker Cell Therapy, Inc.
Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Chief Executive Officer | - |
Formación de John Wilson.
Hamline University | Undergraduate Degree |
University of Minnesota | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MARKER THERAPEUTICS, INC. | Health Technology |
ALLOVIR, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Cellex Biosciences, Inc. | Distribution Services |
Wilson Wolf Manufacturing Corp.
Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Health Technology |
Marker Cell Therapy, Inc.
Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Commercial Services |
- Bolsa de valores
- Insiders
- John Wilson